Downloading...
Download

Bladdercancer

Photocure $PHO Partners with Asieris on Hexvix in ChinaPhotocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan Agreement Expands Photocure’s Hexvix®/Cysview® Franchise Footprint to over 30 Countries Oslo, Norway January 26, 2021, Photocure ASA (PHO:OSE): The Bladder Cancer Company focused on delivering transformative solutions to improve the lives of bladder cancer patients, announces that it has entered into a partnership agreement with Asieris MediTech Co., Ltd. (Asieris), a division of Jiangsu Yahong Meditech Co., Ltd., whereby Asieris has obtained exclusive rights to register and commercialize Hexvix® in Mainland China and Taiwan.
OSL:PHOLong
by savepiginvest
Photocure $PHO trading above 50 and 200 SMA after Q2 reportRecent oversubscribed equity offerings done at 76 and 65,5 NOK after repurchasing global Hexvix ownership from Ipsen now securely in the money. Recent newsflow: 13.08.2020 Photocure appoints Genotests as exclusive partner for Hexvix in Chile 08.07.2020 Photocure's partner Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 (Cevira) 01.07.2020 Photocure appoints Susanne Strauss as Vice President and General Manager of Europe 24.06.2020 Private placement successfully placed - NOK 76 27.04.2020 Private placement successfully placed - NOK 65,5 27.04.2020 PHOTOCURE REGAINS WORLDWIDE RIGHTS OF HEXVIX
OSL:PHOLong
by savepiginvest
Photocure $PHO.OL trade above last major resistance on US patentPatent covering the use of Blue Light Cystoscopy (BLC®) with Hexvix as neoadjuvant* therapy in the treatment of bladder cancer in patients who are scheduled for a cystectomy. Early stage study results have shown an antitumor effect and induced systemic immune effects of hexaminolevulinate (HAL) and blue light in an orthotopic model of rat bladder cancer. Photocure has the intention to further investigate Hexvix for its therapeutic effect and the patent is a result of Photocure’s continued focus on securing intellectual property rights for its research results and pipeline activities. The patent was issued on 11 February 2020 and will expire in December 2036. * Neoadjuvant therapy: treatment (such as chemotherapy) administered before primary cancer treatment (such as surgery) to enhance the outcome of primary treatment Photocure OSL:PHO IR news release: photocure.com
OSL:PHOLong
by savepiginvest
Photocure $PHO.OL stock trade above resistance, close at 5yr hghRecent news by OSL:PHO : Randomized phase 3 study in Denmark demonstrates significant advantage in Bladder Cancer for Hexvix/Cysview blue light cystoscopy over standard white light variant: photocure.com At Q3 2019 Photocure reported continued record growth in the US as well as upfront payments from Chinese partner Asieris: photocure.com Further improvements for US reimbursements for Cysview from january 2020: photocure.com Technical analysis: Technical indicators sliding into high momentum and near overbought values at this price level, so any entry should be done with clear considerations of short term risks.
OSL:PHO
by savepiginvest
Photocure $PHO.OL renewed breakout watch ahead of Q2 reportInvestors are eagerly awaiting Photocures OSL:PHO Q2 2019 report to get a more indepth description of the recently announced Cevira partnership deal. Also key is the information about the current growth rate on Cysview sales in US. NOK 60-64 is a key level of expected resistance, as it is where the share price peaked in 2018, while a negative reaction could easily mean a pullback well below the NOK 50 level, which mean that an entry ahead of the upcoming Q2 presentation should be made with a keen eye on risk management. Recent Edison Analysis after Cevira Deal announcement, BUY target price 70 NOK: www.edisongroup.com
OSL:PHO
by savepiginvest
Photocure $PHO.OL breakout watch on strong Cysview expectationsPhotocure $PHO.OL approaching relevant resistance levels and a breakout to the upside could easily be triggered as the market cap of the company is still low. Recent Edison analysis quote: " Phenomenal US growth Q418 sales in the US increased 81% to NOK18.4m and are up 50% over the course of 2018 with a clear acceleration in the second half of the year. Unit sales increased 69% during the quarter and are up 45% for the year. The total installed base of blue light cystoscopes (both rigid and flexible) increased to 157, up 51% from 104 at the beginning of 2018." www.edisongroup.com
OSL:PHO
by savepiginvest
1
Photocure $PHO.OL stock rally ahead of Q4 report - One to watchPhotocure stock reacted with a heavy (overdone?) correction after the Q3 report, but has recovered nicely in later weeks. As mentioned in an earlier TradingView analysis ( ), NOK 36 and downwards presented a very good buying opportunity, which culminated when the correction bottomed at NOK 32,5 which was a very solid resistance upwards for a long time. Entry at these levels should probably be done with a keen eye on risk management and new investors may want to wait for the soon to come Q4 2018 report before making a move, but the long term uptrend looks promising, and at a valuation of only 113 million USD this Norwegian microcap could go a long way yet. Quoting Pengana capital about their position in Photocure: "Photocure has a current market capitalisation of USD $130 million and we estimate 2018 revenue of USD $25 million which is small compared to the potential US market opportunity valued at $1.3 billion. The company has also had great success in selling its product in Europe, with an 80% penetration in bladder surgery procedures in Scandinavia followed by 30% in Germany." www.raskmedia.com.au
OSL:PHO
by savepiginvest